Use of Fenofibrate for patients with primary Sclerosing Cholangitis - 18/06/19
Doi : 10.1016/j.clinre.2018.11.017
Sherine M Abdalla, Adriana Dejman, Virginia Clark, Cynthia Levy ⁎ 
Division of Hepatology, Department of Medicine, University of Miami, Jackson Medical Towers, 1500 NW, 12th avenue, Suite 1101, Miami, FL, USA
⁎Corresponding author at: Division of Hepatology, Department of Medicine, University of Miami, Jackson Medical Towers, 1500 NW, 12th avenue, Suite 1101, Miami, 33136 FL USADivision of HepatologyDepartment of MedicineUniversity of MiamiJackson Medical Towers, 1500 NW12th avenue, Suite 1101MiamiFL33136USA
Il testo completo di questo articolo è disponibile in PDF.
Mappa
© 2019
Elsevier Masson SAS. Tutti i diritti riservati.
Vol 43 - N° 3
P. e33-e36 - Giugno 2019 Ritorno al numero
Articolo precedente
- Autoimmune hepatitis in patients with multiple sclerosis: The role of immunomodulatory treatment
- Eirini I. Rigopoulou, Sofia Gyftaki, Pinelopi Arvaniti, Vana Tsimourtou, George K. Koukoulis, Georgios Hadjigeorgiou, George N. Dalekos
- Commentary to the paper entitled “Increased incidence of Campylobacter enteritis and their quinolone resistance between 2010 and 2015: Results of a French national observatory conducted in 21 general hospitals (CHG)”
- Isabelle Kempf, Cécile Adam, Claire Chauvin
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?